Investors

Corporate Profile

Strongbridge Biopharma is a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs. Founded in 1996, the Company is publicly traded on the NASDAQ Global Market under the ticker symbol SBBP.

| (Common Stock)

Stock chart for: SBBP.O. Currently trading at $4.40 with a 52 week high of $6.24 and a 52 week low of $2.00.

Data provided by Nasdaq. Minimum 15 minutes delayed.

Press Releases

Strongbridge Biopharma plc to Host First Quarter 2019 Financial Results Conference Call on May 1, 2019

04/24/19

DUBLIN, Ireland and TREVOSE, Pa. , April 24, 2019 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc , (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that...

Read More
Strongbridge Biopharma plc Announces Upcoming Presentation of New Data from Phase 3 SONICS Study of RECORLEV™ (levoketoconazole) for the Treatment of Endogenous Cushing’s Syndrome at the 2019 American Association of Clinical Endocrinologists (AACE) Annual

04/15/19

DUBLIN, Ireland and TREVOSE, Pa. , April 15, 2019 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc , (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that...

Read More

Investors

Investors

Corporate Profile

Press Releases

Strongbridge Biopharma plc to Host First Quarter 2019 Financial Results Conference Call on May 1, 2019

Strongbridge Biopharma plc Announces Upcoming Presentation of New Data from Phase 3 SONICS Study of RECORLEV™ (levoketoconazole) for the Treatment of Endogenous Cushing’s Syndrome at the 2019 American Association of Clinical Endocrinologists (AACE) Annual

Upcoming Events